Louisiana-Pacific Expects Siding FY23 Net Sales To Decrease By ~10% YoY; For 4Q23 Sees OSB’s Net Sales Decline Sequentially By ~30%, Expects Adjusted EBITDA Of $60M-$80M

Outlook Our guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below under "Forward-Looking

Outlook

Our guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below under “Forward-Looking Statements.”

  • Siding full-year 2023 Net sales is expected to decrease year-over-year by approximately 10%
  • OSB fourth quarter 2023 Net sales is expected to be sequentially lower than the third quarter 2023 by approximately 30%, assuming that OSB prices published by Random Lengths remain unchanged from those published on October 27, 2023 (this is an assumption for modeling purposes and not a price forecast)
  • Under these assumptions, fourth quarter 2023 Adjusted EBITDA(2) is expected to be $60 million to $80 million
  • Given our current outlook, capital expenditures for 2023 are expected to be in the range of $280 million to $295 million, including $100 million to $105 million for mill conversions, $130 million to $135 million for sustaining maintenance, and $50 million to $55 million for other strategic growth projects.
Total
0
Shares
Related Posts
Read More

AstraZeneca’s Imfinzi (Durvalumab) In Combination With Imjudo (Tremelimumab) Plus Platinum-based Chemotherapy Has Been Approved By The Us Fda For The Treatment Of Adult Patients With Stage Iv (Metastatic) Non-small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).

AZN